Lung Cancer:: Prevention, Management, and Emerging Therapies

ISBN-13: 9781607615231 / Angielski / Twarda / 2010 / 538 str.

David J. Stewart

Opis

Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as discussing our track record to date in exploiting them.

Recenzje

From the reviews:

"This comprehensive review of prevention and treatment strategies for malignancies of the thorax thoroughly investigates tumor biology and discusses established and emerging therapies. ... The book is written for a wide audience that includes pathologists, pulmonologists, medical oncologists, radiation oncologists, and surgical oncologists. ... I would highly recommend this book to anyone interested in current and future therapies for lung cancer. This is one of the most comprehensive and up-to-date accounts of the field." (Nagendra S. Koneru, Doody's Review Service, July, 2010)

Spis treści

Molecular pathology of lung cancer: Alejandro Corvalan and Ignacio Wistuba Tumor microenvironment: Tonya C. Walser, Jane Yanagawa, Edward Garon, Jay M. Lee, Steven Dubinett Racial and ethnic diversity in lung cancer: Carol J. Etzel, Sumesh Kachroo Pharmacogenetics of lung cancer: Xifeng Wu, Jian Gu Lung cancer prevention Nir Peled, Robert L. Kieth, Fred Hirsch Adjuvant and neoadjuvant therapy of non-small cell lung cancer: Katherine Pisters Chemoradiotherapy for inoperable non-small cell lung cancer: James Cox and David J. Stewart Management of advanced non-small cell lung cancer- front line treatment: William N. William Jr. and David J. Stewart Chemotherapy in previously-treated patients with non-small cell lung cancer: Frank V. Fossella Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer: Paul Wheatley-Price and Frances A, Shepherd Angiogenesis inhibitors in lung cancer : Leora Horn and Alan Sandler Other molecular targeted agents in non-small cell lung cancer: Benjamin Besse and Jean Charles Soria Vaccine therapy for lung cancer: John Nemunaitis and Jack Roth Gene-based therapies for lung cancer: John Nemunaitis and Jack Roth Lung cancer resistance to chemotherapy: David J. Stewart Small cell carcinoma: Emer Hanrahan and Bonnie Glisson Mesothelioma: Mary Frances McAleer, Reza J. Mehran, and Anne Tsao Advances in oncology clinical research statistical and study design methodologies: B. Nebiyou Bekele Palliativecare for patients with lung cancer: David Hui and Eduardo Bruera The future of lung cancer: Sophie Sun, Joan H. Schiller, Monica Spinola, John Minna

Blurb

This comprehensive resource provides authoritative knowledge of the most up-to-date prevention and treatment strategies for thoracic malignancies. Established and investigational therapies are placed in the context of tumor biology for a full understanding of the pharmacogenetics, etiology, and changing epidemiology of lung cancer. Expert clinicians detail the function of predictive and prognostic factors in the utilization of chemo-radiotherapy, adjuvant and neoadjuvant treatment, and targeted agents. The promises and potential pitfalls of investigational strategies are evaluated with exceptional insight and clarity, with unique attention paid to the mechanisms of drug resistance and targets for lung cancer treatment and prevention. Lung Cancer: Prevention, Management, and Emerging Therapies engages the entire spectrum of therapeutic modalities with focus on systemic approaches. Disease coverage includes newly diagnosed and recurrent non-small cell lung cancer, small cell carcinoma, and mesothelioma. Critical examination of the impact, methodology, and design of clinical trials is presented along with new paradigms for personalized approaches and individual risk assessment.